tiprankstipranks
PolarityTE (RGTPQ)
OTHER OTC:RGTPQ

PolarityTE (RGTPQ) Stock Price & Analysis

523 Followers

RGTPQ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range<$0.01 - $0.77
Previous Close$0.05
Volume1.73K
Average Volume (3M)8.69K
Market Cap
$376.56K
Enterprise Value-$3.53M
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)>-0.1
Beta4.19
Nov 14, 2023
EPS EstimateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding7,376,231
10 Day Avg. Volume966
30 Day Avg. Volume8,692
Standard Deviation0.63
R-Squared0.01
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-0.03
Price to Sales (P/S)0.46
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-48.33
Enterprise Value/Gross Profit-17.82
Enterprise Value/Ebitda-3.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

RGTPQ FAQ

What was PolarityTE’s price range in the past 12 months?
PolarityTE lowest stock price was <$0.01 and its highest was $0.77 in the past 12 months.
    What is PolarityTE’s market cap?
    Currently, no data Available
    When is PolarityTE’s upcoming earnings report date?
    PolarityTE’s upcoming earnings report date is Nov 14, 2023 which is 112 days ago.
      How were PolarityTE’s earnings last quarter?
      Currently, no data Available
      Is PolarityTE overvalued?
      According to Wall Street analysts PolarityTE’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does PolarityTE pay dividends?
        PolarityTE pays a Notavailable dividend of $50.25 which represents an annual dividend yield of N/A. See more information on PolarityTE dividends here
          What is PolarityTE’s EPS estimate?
          PolarityTE’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does PolarityTE have?
          PolarityTE has 7,376,231 shares outstanding.
            What happened to PolarityTE’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of PolarityTE?
            Currently, no hedge funds are holding shares in RGTPQ
            ---

            Company Description

            PolarityTE

            PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant. The company was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.
            ---

            RGTPQ Stock 12 Months Forecast

            Average Price Target

            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2022","6":"Oct<br/>2022","9":"Jan<br/>2023","12":"Mar<br/>2023","25":"Mar<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.6646153846153846,0.6092307692307692,0.5538461538461539,0.49846153846153846,0.4430769230769231,0.38769230769230767,0.3323076923076923,0.27692307692307694,0.22153846153846157,0.1661538461538462,0.11076923076923084,0.055384615384615365,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.6646153846153846,0.6092307692307692,0.5538461538461539,0.49846153846153846,0.4430769230769231,0.38769230769230767,0.3323076923076923,0.27692307692307694,0.22153846153846157,0.1661538461538462,0.11076923076923084,0.055384615384615365,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.6646153846153846,0.6092307692307692,0.5538461538461539,0.49846153846153846,0.4430769230769231,0.38769230769230767,0.3323076923076923,0.27692307692307694,0.22153846153846157,0.1661538461538462,0.11076923076923084,0.055384615384615365,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6,"date":1648771200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.3,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.52,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.35,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.02,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.87,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.74,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.72,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.66,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.82,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.73,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.72,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Similar Stocks
            Company
            Price & Change
            Follow
            Plus Therapeutics
            Vericel
            Moleculin Biotech
            Verastem

            Best Analysts Covering RGTPQ

            1 Year
            Unknown AnalystNorthland Securities
            Not Ranked
            1 Year Success Rate
            0/0 ratings generated profit
            0%
            1 Year Average Return
            0.00%
            reiterated a buy rating 11 months ago
            Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis